269 related articles for article (PubMed ID: 8944370)
21. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
Loftus EV; Kane SV; Bjorkman D
Aliment Pharmacol Ther; 2004 Jan; 19(2):179-89. PubMed ID: 14723609
[TBL] [Abstract][Full Text] [Related]
22. Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis.
Cuffari C; Pierce D; Korczowski B; Fyderek K; Van Heusen H; Hossack S; Wan H; Edwards AY; Martin P
Drug Des Devel Ther; 2016; 10():593-607. PubMed ID: 26893546
[TBL] [Abstract][Full Text] [Related]
23. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G
Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559
[TBL] [Abstract][Full Text] [Related]
24. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.
Prakash A; Markham A
Drugs; 1999 Mar; 57(3):383-408. PubMed ID: 10193690
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group.
Fockens P; Mulder CJ; Tytgat GN; Blok P; Ferwerda J; Meuwissen SG; Tuynman HA; Dekker W; Gasthuis K; van Hees PA
Eur J Gastroenterol Hepatol; 1995 Nov; 7(11):1025-30. PubMed ID: 8680900
[TBL] [Abstract][Full Text] [Related]
26. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.
Sandborn WJ; Hanauer SB
Aliment Pharmacol Ther; 2003 Jan; 17(1):29-42. PubMed ID: 12492730
[TBL] [Abstract][Full Text] [Related]
27. Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation.
Christensen LA; Fallingborg J; Jacobsen BA; Abildgaard K; Rasmussen HH; Hansen SH; Rasmussen SN
Aliment Pharmacol Ther; 1994 Jun; 8(3):289-94. PubMed ID: 7918923
[TBL] [Abstract][Full Text] [Related]
28. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
Christensen LA
Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
[TBL] [Abstract][Full Text] [Related]
29. A clinical trial on absorption and N-acetylation of oral and rectal mesalazine.
Dilger K; Trenk D; Rössle M; Cap M; Zähringer A; Wacheck V; Remmler C; Cascorbi I; Kreisel W; Novacek G
Eur J Clin Invest; 2007 Jul; 37(7):558-65. PubMed ID: 17576207
[TBL] [Abstract][Full Text] [Related]
30. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
Nakajima H; Munakata A; Yoshida Y
J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
[TBL] [Abstract][Full Text] [Related]
31. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.
Harris MS; Lichtenstein GR
Aliment Pharmacol Ther; 2011 May; 33(9):996-1009. PubMed ID: 21385194
[TBL] [Abstract][Full Text] [Related]
32. Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis.
Lauritsen K; Staerk Laursen L; Bukhave K; Rask-Madsen J
Gut; 1988 Jul; 29(7):974-82. PubMed ID: 2840367
[TBL] [Abstract][Full Text] [Related]
33. Mucosal concentrations of N-acetyl-5-aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine.
Fukuda T; Naganuma M; Takabayashi K; Hagihara Y; Tanemoto S; Nomura E; Yoshimatsu Y; Sugimoto S; Nanki K; Mizuno S; Mikami Y; Fukuhara K; Sujino T; Mutaguchi M; Inoue N; Ogata H; Iwao Y; Abe T; Kanai T
J Gastroenterol Hepatol; 2020 Nov; 35(11):1878-1885. PubMed ID: 32250471
[TBL] [Abstract][Full Text] [Related]
34. [Effectiveness of new, once-daily 5-aminosalicylic acid in the treatment of ulcerative colitis].
Lakatos PL; Lakatos L
Orv Hetil; 2009 Mar; 150(9):397-404. PubMed ID: 19228568
[TBL] [Abstract][Full Text] [Related]
35. Once daily 5-aminosalicylic acid for the treatment of ulcerative colitis; are we there yet?
Lakatos PL; Lakatos L
Pharmacol Res; 2008; 58(3-4):190-5. PubMed ID: 18801439
[TBL] [Abstract][Full Text] [Related]
36. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis.
Nikfar S; Rahimi R; Rezaie A; Abdollahi M
Dig Dis Sci; 2009 Jun; 54(6):1157-70. PubMed ID: 18770034
[TBL] [Abstract][Full Text] [Related]
37. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine.
Rao SS; Cann PA; Holdsworth CD
Scand J Gastroenterol; 1987 Apr; 22(3):332-6. PubMed ID: 2884724
[TBL] [Abstract][Full Text] [Related]
38. Pharmacology of olsalazine.
Campbell DE; Berglindh T
Scand J Gastroenterol Suppl; 1988; 148():7-12. PubMed ID: 3067340
[TBL] [Abstract][Full Text] [Related]
39. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.
Hanauer SB
Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():37-40. PubMed ID: 16961743
[TBL] [Abstract][Full Text] [Related]
40. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study.
Yokoyama H; Takagi S; Kuriyama S; Takahashi S; Takahashi H; Iwabuchi M; Takahashi S; Kinouchi Y; Hiwatashi N; Tsuji I; Shimosegawa T
Inflamm Bowel Dis; 2007 Sep; 13(9):1115-20. PubMed ID: 17455207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
